HOME | CONFERENCE AGENDA | SPEAKERS | DEAL OF THE YEAR | REGISTER | CONTACT US |
![]() |
ALLICENSE AGENDA WEDNESDAY JUNE 8, 2016 Moscone Center South 102, San Francisco, CA |
PLEASE NOTE: This is a working agenda. Check back for updates and announcements! A BIG THANK YOU TO THE ALLICENSE CONTENT ADVISORY BOARD The work which the Allicense Planning Council has contributed is invaluable to the success of Allicense. The Allicense Planning Council has devoted invaluable effort to the success of Allicense. Their time, energy and contributions are what make Allicense the unparalleled forum for dealmaking it is known for. |
2018 © Clarivate Analytics
|
TIME 8:00-815 8:15-8:45 8:45-9:45 9:45-10:15 10:15-10:30 10:30-11:30 11:30-12:00 12:00-1:15 1:15-1:30 1:30-2:15 2:15-3:15 3:15-3:45 3:45-4:45 4:45 - 5:00 5:00 -6:00 Until 6:30 6:00 - 8:00 |
DURATION CONTENT MODERATOR/SPEAKER CONFIRMED PANELISTS |
15 min |
30 min |
60 min Panel Discussion: At What Price? Drug Pricing Clarity and Solutions (panel description below) |
30 min AM Networking Break |
15 min Data Presentation: Changing Financial Markets for Biopharma Innovations |
60 min |
30 min |
75 min Boxed Lunches & Speaker: Rare Disease Patient Advocacy and the Industry Lunch and networking with 45 min presentation |
15 min |
45 min |
30 min Networking Break & Deal of the Year Voting |
60 min |
60 min Award Celebration: Donald Johnston, Moderator Allicense 2016 Breakthrough Celebrate the winners at our private Deal of the Year Winners onsite Allicense cocktail reception |
Shuttles to BIO Reception BIO Evening Reception "Summer of Love" party at San Francisco City Hall and Civic Plaza |
60 min Rapid Fire Presentations: |
Representatives from the buyside and sellside of the Allicense 2016 Breakthrough Deal nominees (5 M&A and 5 licensing transactions) |
15 min Conference Wrap Up: Laura Vitez, Principal Business Analyst, Thomson Reuters |
PANEL DESCRIPTIONS 8:00-8:15 AM Conference Kick Off: Let’s Play Chess! Presented by Peter Kolchinsky, PhD, Managing Director and Portfolio Manager, RA Capital Management LLC Mapping the chessboard: the competitive game theory that governs how companies can, should, and yet only sometimes do, assimilate all the necessary new technologies to grow and defend against disruption. Where are the unmet needs, what are the opportunities, and who should be talking to whom, from the perspective of an evidence- based crossover investor. 8:45-9:45 AM Panel Discussion: At What Price? Drug Pricing Clarity and Solutions Presented by James C. Robinson, PhD, MPH, Leonard D. Schaeffer Professor of Health Economics, University of California at Berkeley Though drug cost-valuation debates aren't new, the battle exploded onto a global center stage in 2015 when a previously little-known CEO unapologetically hiked the price of an in-licensed generic drug 5500%. Simultaneously patients’ voices have grown louder, especially given increased consumer cost sharing. In the U.S., the pending presidential election gives politicians more ammunition than ever to enact price regulations that could have an enormous impact on innovation. It’s a perfect storm. As public criticism grows, rather than rehashing old arguments, experts are gathering at Allicense for a candid discussion providing fresh clarity and proposing a variety of pro-active, granular, workable solutions to the ongoing drug pricing controversies. 10:30-11:30 AM Investing and Exiting and Doing It Again: Private, Crossover, and Public Strategies Presented by Jonathan Norris, JD, Managing Director, Silicon Valley Bank What are the current trends in financing and exits for venture-backed biopharma companies? Where are the active investors deploying their capital? What is the role of crossover investors in 2016? Has the influence of the ever-changing public market changed VC’s underlying investment theses? Will the IPO window continue in 2016? Is early stage M&A a long term trend for the industry? 1:30-2:15 PM Panel Discussion: Fostering and Transferring Innovation: Working Together to keep the Ecosystem Healthy Presented by David Dunn, PhD, Practice Lead, Portfolio and Licensing Professional Services, Thomson Reuters Industry has always relied upon ground-breaking discoveries originating from academic and other early-stage research. These discoveries range from new insight into disease mechanisms and potential novel therapeutic points of intervention, through inventive therapeutic approaches to unmet medical needs and their validation in the clinic. There are great opportunities at the interface between academia and commercial enterprise; yet there are also multiple challenges. Issues include the negotiation of rights of ownership, financial terms, management of joint research efforts, and transfer of knowledge. This panel will pull together industry and academia veterans who have navigated the challenges of translating discoveries into commercial opportunities. 3:45-4:45 PM Panel Discussion: Strategies Supporting Breakthrough Innovations Presented by Karl Handelsman, Founder, Codon Capital Our panel of serial "value creators" will describe their approach to building companies through BD. Many key decisions open up the ability to rapidly create breakthrough innovations: collaborate or control, build or partner, financing pathways, best practices of engaging with Universities, KOLs, Pharma. In addition to a group experience moving from early startup to IPO, we will discuss how the dealmaking ecosystem will continue to evolve. |
Peter Kolchinsky, PhD Managing Director and Portfolio Manager, RA Capital Management LLC |
Conference Kick Off Let’s Play Chess! (panel description below) |
Morning Keynote Address: Pricing and Patient Access: Basis for Agreement between Manufacturers and Insurers? |
James C. Robinson, PhD, MPH Leonard D. Schaeffer Professor of Health Economics, University of California at Berkeley; Author of “Purchasing Medical Innovation: The Right Technology, for the Right Patient, at the Right Price” |
• Anita Chawla, PhD, Managing Principal, Analysis Group • Cameron Durrant, MD, CEO, KaloBios • Paul Hastings, CEO, OncoMed • Amy Bricker, VP, Supply Chain Management, Express Scripts |
James C. Robinson, PhD, MPH Leonard D. Schaeffer Professor of Health Economics, University of California at Berkeley |
Jonathan Norris, JD, Managing Director, Silicon Valley Bank |
• Chen Yu, MD, Managing Partner, Vivo Capital • Dan Estes, PhD, Principal, Frazier Healthcare • Simeon George, MD, Partner, SR One • Peter Kolchinsky, PhD, Managing Director, RA Capital |
Panel Discussion: Investing and Exiting and Doing It Again: Private, Crossover, and Public Strategies |
Laura Vitez, Principal Business Analyst, Thomson Reuters |
Data Presentation: Dealmakers Index and the Current Dealmaking Landscape |
Tricia Mullins, VP, Strategic Alliances, Global Genes Rare disease group focused on public policy and industry interface |
David Dunn, PhD, Practice Lead Portfolio and Licensing Professional Services, Thomson Reuters |
Panel Discussion: Fostering and Transferring Innovation: Working Together to keep the Ecosystem Healthy |
Data Presentation: Academic/Commercial Interface Current Dealmaking |
David Dunn, PhD, Practice Lead Portfolio and Licensing Professional Services, Thomson Reuters |
• Tom Duley, JD, Partner, King and Spalding • June Lee, MD, Director, Early Translational Research/ Catalyst Program, University California at San Francisco • Clifford Stocks, CEO, OncoResponse • Ben Thorner, JD, VP BD&L, Head of North American Innovation Hubs, Merck • Mona Wan, Associate Director, Stanford Office of Technology Licensing |
Donald Johnston, Moderator Senior Director, Current Awareness, Thomson Reuters |
• Kent Hawryluk, CBO, Avidity Nanomedicines • John Mulligan, PhD, Scientific Founder, Good Therapeutics • Arthur Sands, MD, PhD, CEO, Nurix • Richard Soll, PhD, SVP, International Discovery Service, WuXi AppTec • Christopher Denn, Partner, Goodwin Procter |
Panel Discussion: Strategies Supporting Breakthrough Innovations (panel description below) |
Karl Handelsman, Founder, Codon Capital |
Jonathan Norris, JD, Managing Director, Silicon Valley Bank |
DON JOHNSTON Senior Director, Current Awareness, Thomson Reuters LYNN YOFFEE News Director, BioWorld, Thomson Reuters KE ZHANG Business Development Segment Lead, Thomson Reuters |
SOUGATO DAS Director, Partnering and Business Development, BIO SARAH ARTH Managing Director, Education, BIO |